Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

13.2%

5 terminated/withdrawn out of 38 trials

Success Rate

83.9%

-2.6% vs industry average

Late-Stage Pipeline

18%

7 trials in Phase 3/4

Results Transparency

85%

22 of 26 completed trials have results

Key Signals

1 recruiting22 with results

Enrollment Performance

Analytics

Phase 2

23(69.7%)

Phase 3

7(21.2%)

Phase 1

3(9.1%)

33Total

Phase 2(23)

Phase 3(7)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT05644808Active Not Recruiting

MYLUNG Consortium Study Protocol 2

Role: lead

NCT00248287Phase 2Active Not Recruiting

PhII ICb With/Without Erbitux in MBC Pts

Role: lead

NCT04782687Phase 2Active Not Recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Role: lead

NCT03379428Phase 1Active Not Recruiting

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Role: lead

NCT02187991Phase 2Completed

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Role: lead

NCT05885698Recruiting

MYLUNG Consortium Part 3: Observational Study

Role: lead

NCT06335758Unknown

Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.

Role: collaborator

NCT01847274Phase 3Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Role: collaborator

NCT00493870Phase 3Completed

TAC Versus TC for Adjuvant Breast Cancer

Role: lead

NCT02229149Phase 2Terminated

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Role: lead

NCT02229136Phase 2Completed

Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus

Role: lead

NCT01905592Phase 3Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Role: collaborator

NCT00887536Phase 3Completed

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Role: collaborator

NCT02000882Phase 2Completed

STAR Cape+BKM120 MBC With Brain Met

Role: lead

NCT02032277Phase 3Completed

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Role: collaborator

NCT02425683Phase 2Terminated

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Role: lead

NCT00252564Phase 3Completed

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Role: lead

NCT00384839Phase 2Completed

Vidaza to Restore Hormone Thx Prostate

Role: lead

NCT01744197Phase 2Completed

Synera Venipuncture Pain